SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company") today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warra ...

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced that its Antib ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Elutia Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upcoming Heart Rhythm Society's annual meeting (HRS 2024), where it will showcase its innovative CanGaroo® BioEnvelope product line. Designed specifically for cardiac implantable electronic devices (CIEDs), the biologic matrix of the envelope works with the body to promote a natural healing response and enhance device ...

These statements involve material risks and uncertainties, that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including Elutia's annual report on Form 10-K for the year ended December 31, 2023, ...

Exhibit 99.1 · Generated strong revenue growth for proprietary product lines in the first quarter of 2024, led by SimpliDerm net sales increasing 55% compared to the first quarter of 2023 · FDA interactions regarding CanGarooRM, Elutia's antibiotic-eluting biologic envelope, continue to be positive · Addressing the final details for CanGarooRM clearance; anticipate FDA decision in the second quarter of 2024 · Preparing for launch of CanGarooRM in the second half of 2024 First Quarter 2024 Financial Results ...

SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 3:00 p.m. ET (12:00 p.m. PT). Planet MicroCap Showcase: VEGAS 2024Presentation Date: Wednesday, May 1, 2024Presentation Time: 3:00 p.m. ET (12:00 p.m. PT)Web ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Elutia Inc. (Exact name of registrant as specified in its charter) Delaware 47-4790334 (State or other jurisdiction of (I.R.S. Emp ...

Company Participants Matt Steinberg - Finn Partners Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator I will now turn the conference over to Matt Steinberg with Finn Partners. Thank you. You may begin. Thank you, operator, and thank you all for participating in today's call. Earlier today at Elutia released financial results for the quarter and full-year ended December 31, 2023. A copy of the press release is available on the company's website. These statements involve mater ...

Exhibit 99.1 Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024 SILVER SPRING, Md., March 7, 2024 — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023. Business Highlights: · Achieved strong annual revenue growth for both proprietary product lines, with sales increasing for SimpliDerm by 38% and CanGa ...